D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...
MedPage Today on MSN
CAR-T immune toxicity linked to non-relapse mortality risk in myeloma
Study suggests CD4+ T cells mediate these immune-related toxicities ...
The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) for patients with newly ...
Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...
Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more ...
The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...
New draft guidance from the FDA on multiple myeloma endpoints reflects the new technology available to assess disease and how patient journeys have changed with better treatments.
Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Smoldering multiple myeloma is a complex, intermediary stage ...
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results